Advisors Preferred LLC Makes New Investment in Humana Inc. $HUM

Advisors Preferred LLC acquired a new stake in shares of Humana Inc. (NYSE:HUM) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 1,882 shares of the insurance provider’s stock, valued at approximately $475,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC raised its position in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 46 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in Humana in the 1st quarter worth $37,000. CVA Family Office LLC raised its stake in Humana by 63.4% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the insurance provider’s stock worth $54,000 after acquiring an additional 85 shares during the last quarter. Ransom Advisory Ltd purchased a new position in Humana in the 1st quarter worth $66,000. Finally, Transamerica Financial Advisors LLC raised its stake in Humana by 1,027.6% in the 1st quarter. Transamerica Financial Advisors LLC now owns 327 shares of the insurance provider’s stock worth $87,000 after acquiring an additional 298 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

HUM has been the topic of a number of recent research reports. Truist Financial set a $300.00 target price on Humana in a research note on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a research note on Wednesday, October 8th. Royal Bank Of Canada raised their target price on Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a research report on Thursday, August 21st. Evercore ISI assumed coverage on Humana in a research report on Monday, September 22nd. They set an “in-line” rating and a $295.00 target price on the stock. Finally, Wolfe Research raised their target price on Humana from $283.00 to $313.00 and gave the company an “outperform” rating in a research report on Monday, October 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $299.22.

Humana Trading Up 0.7%

Shares of Humana stock opened at $280.19 on Tuesday. The stock has a market cap of $33.70 billion, a P/E ratio of 21.50, a P/E/G ratio of 1.71 and a beta of 0.42. The stock’s 50 day simple moving average is $280.99 and its 200-day simple moving average is $258.73. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, December 26th. Humana’s payout ratio is presently 27.17%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.